Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 6Small Cell Lung Carcinoma 4Cholangiocarcinoma 4Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic Cancer Metastatic 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × surufatinib × Clear all
NCT07279532 2025-12-12

Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
35 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡